Arterial atherosclerosis in patients with chronic kidney disease and its relationship with serum and tissue endothelin-1. [corrected].

Instruction. We investigated the correlation between atherosclerosis and tissue and serum levels of endothelin-1 in patients with chronic kidney disease (CKD). MATERIALS AND METHODS. Arterial samples were obtained from 35 patients with CKD during arteriovenous fistula placement. Thirty-one patients with cardiovascular disease who underwent coronary artery bypass graft (CABG) were selected as the atherosclerotic group, and a piece of their aorta punched during CABG was obtained. Also, a small piece of the renal artery was dissected during donation in 24 kidney donors (control group). Tissue endothelin-1 level was measured and atherosclerosis grading was determined by pathologic examination. Serum levels of endothelin-1 were also measured in the three groups. Results. The mean tissue endothelin-1 levels were 10.73+/-7.57 pg/mL, 12.16 +/- 3.95 pg/mL, and 0.93 +/- 1.06 pg/mL in the patients with CKD, those with CABG, and donors, respectively (P < .001). The mean serum endothelin-1 level was 25.23 +/- 15.15 pg/mL in the patients with CKD, 21.13 +/- 17.22 pg/mL in the patients with CABG, and 2.66 +/- 1.51 pg/mL in the donors (P < .001). Atherosclerosis grades correlated with tissue endothelin-1 level (r = 0.823, P < .001) and serum endothelin-1 level (r = 0.608, P < .001) in the patients with CKD. Multiple regression analysis showed tissue endothelin-1 level as the main predicting factor of atherosclerosis (P < .001). CONCLUSIONS. Tissue endothelin-1 concentration is more important than serum endothelin-1 or lipids levels in prediction of atherosclerosis. Thus, blockade of tissue endothelin-1 receptors with its antagonists may prevent atherosclerosis progression.

[1]  K. Hirata,et al.  Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. , 2009, Cardiovascular research.

[2]  M. Banach,et al.  Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension , 2009, Clinical and experimental hypertension.

[3]  P. Little,et al.  Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. , 2008, Current vascular pharmacology.

[4]  R. Shah.  Endothelins in health and disease. , 2007, European journal of internal medicine.

[5]  Achmad Rudijanto,et al.  The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. , 2007, Acta medica Indonesiana.

[6]  D. Stewart,et al.  Regulation of Endothelin-1 by Angiopoietin-1: Implications for Inflammation , 2006, Experimental biology and medicine.

[7]  I. Yamaguchi,et al.  Endothelin Antagonism Suppresses Plasma and Cardiac Endothelin-1 Levels in SHRSPs at the Typical Hypertensive Stage , 2006, Experimental biology and medicine.

[8]  A. Ishihata,et al.  Role of Angiotensin II and Endothelin‐1 Receptors in Aging‐Related Functional Changes in Rat Cardiovascular System , 2006, Annals of the New York Academy of Sciences.

[9]  D. Webb,et al.  The endothelin system and its antagonism in chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[10]  R. Kranzhöfer,et al.  Endothelin-1 induces CD40 but not IL-6 in human monocytes via the proinflammatory transcription factor NF-kappaB. , 2005, European journal of medical research.

[11]  T. Lüscher,et al.  Protection of endothelial function. , 2005, Handbook of experimental pharmacology.

[12]  J. Després,et al.  Endothelin-1 levels and cardiovascular risk factors in renal transplant patients. , 2004, Clinical Biochemistry.

[13]  V. Liakopoulos,et al.  Plasma Endothelin-1 in Hemodialysis Treatment - the Influence of Hypertension , 2004, Journal of cardiovascular pharmacology.

[14]  A. I. Teplyakov.  Endothelin-1 Involved in Systemic Cytokine Network Inflammatory Response at Atherosclerosis , 2004, Journal of cardiovascular pharmacology.

[15]  C. Ihling,et al.  Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis--novel targets for pharmacotherapy in atherosclerosis. , 2004, Current vascular pharmacology.

[16]  G. Fink,et al.  Endothelin-1 Stimulates Arterial VCAM-1 Expression Via NADPH Oxidase-Derived Superoxide in Mineralocorticoid Hypertension , 2003, Hypertension.

[17]  E. Ritz,et al.  Special characteristics of atherosclerosis in chronic renal failure. , 2003, Clinical nephrology.

[18]  P. Ganz,et al.  Endothelin-1 and Vascular Tone in Subjects With Atherogenic Risk Factors , 2003, Hypertension.

[19]  M. Lebel,et al.  Endothelin-1 in chronic renal failure and hypertension. , 2003, Canadian journal of physiology and pharmacology.

[20]  N. Bousette,et al.  Endothelin-1 in atherosclerosis and other vasculopathies. , 2003, Canadian journal of physiology and pharmacology.

[21]  E. Schiffrin,et al.  Role of endothelin in human hypertension. , 2003, Canadian journal of physiology and pharmacology.

[22]  馬渡 一諭.  Endothelin-1(1-31) Levels are Increased in Atherosclerotic Lesions of the Thoracic Aorta of Hypercholesterolemic Hamsters , 2003 .

[23]  S. Doggrell.  The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system , 2002, Expert opinion on investigational drugs.

[24]  J. Panza,et al.  Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus , 2002, Circulation.

[25]  A. Davenport,et al.  Comparison of the effects of atherosclerosis and nitrate therapy on responses to nitric oxide and endothelin-1 in human arteries in vitro. , 2002, Clinical science.

[26]  FelixBöhm,et al.  Combined Endothelin Receptor Blockade Evokes Enhanced Vasodilatation in Patients With Atherosclerosis , 2002 .

[27]  G. Ahlborg,et al.  Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. , 2002, Clinical science.

[28]  T. Lüscher,et al.  Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice , 2002 .

[29]  M. Dashwood,et al.  Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. , 2002, Atherosclerosis.

[30]  A. Ergul.  Endothelin‐1 and Endothelin Receptor Antagonists as Potential Cardiovascular Therapeutic Agents , 2002, Pharmacotherapy.

[31]  U. Hedin,et al.  Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. , 2002, Atherosclerosis.

[32]  T. Lüscher,et al.  Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. , 2002, Cardiovascular research.

[33]  Y. Yamamoto,et al.  Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[34]  M. Bachem,et al.  Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. , 2001, Journal of molecular and cellular cardiology.

[35]  W. Kiowski,et al.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease , 2001, Current hypertension reports.

[36]  T. Lüscher,et al.  Therapeutic Potential for Endothelin Receptor Antagonists in Cardiovascular Disorders , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[37]  T. Anderson,et al.  Assessment and treatment of endothelial dysfunction in humans. , 1999, Journal of the American College of Cardiology.